Stage I-II low grade non-Hodgkin's lymphoma: prognostic factors and treatment results.

Ron Epelbaum(University of Bern), Yossi Cohen, Michelle Leviov(Haifa Medical Center), A Kuten, Y Ben-Arie, N M Coachman, David Faraggi(Carmel (Israel)), Menachem Ben-Shahar(Technion – Israel Institute of Technology), Nissim Haim(Technion – Israel Institute of Technology)
PubMed
February 1, 1992
Cited by 17

Related Papers

Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279
Endocrinology: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy
|Human Reproduction|1996|266